Aberrant methylation of CDH13 can be a diagnostic biomarker for lung adenocarcinoma
about
Quantitative assessment of the diagnostic role of FHIT promoter methylation in non-small cell lung cancerDiagnosis value of aberrantly expressed microRNA profiles in lung squamous cell carcinoma: a study based on the Cancer Genome Atlas.Aberrant S100A16 expression might be an independent prognostic indicator of unfavorable survival in non-small cell lung adenocarcinoma.
P2860
Aberrant methylation of CDH13 can be a diagnostic biomarker for lung adenocarcinoma
description
2016 nî lūn-bûn
@nan
2016年の論文
@ja
2016年論文
@yue
2016年論文
@zh-hant
2016年論文
@zh-hk
2016年論文
@zh-mo
2016年論文
@zh-tw
2016年论文
@wuu
2016年论文
@zh
2016年论文
@zh-cn
name
Aberrant methylation of CDH13 can be a diagnostic biomarker for lung adenocarcinoma
@ast
Aberrant methylation of CDH13 can be a diagnostic biomarker for lung adenocarcinoma
@en
type
label
Aberrant methylation of CDH13 can be a diagnostic biomarker for lung adenocarcinoma
@ast
Aberrant methylation of CDH13 can be a diagnostic biomarker for lung adenocarcinoma
@en
prefLabel
Aberrant methylation of CDH13 can be a diagnostic biomarker for lung adenocarcinoma
@ast
Aberrant methylation of CDH13 can be a diagnostic biomarker for lung adenocarcinoma
@en
P2093
P2860
P356
P1433
P1476
Aberrant methylation of CDH13 can be a diagnostic biomarker for lung adenocarcinoma
@en
P2093
Jiucun Wang
Lixing Tan
Xiaofeng Chen
Yulong Tan
P2860
P304
P356
10.7150/JCA.15758
P50
P577
2016-11-25T00:00:00Z